Lasofoxifene for postmenopausal women with osteoporosis.
Katzeff
Barbara S
BS
D002289:Carcinoma, Non-Small-Cell Lung / Q000139:chemically induced* / Q000473:pathology; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000139:chemically induced* / Q000473:pathology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D011759:Pyrrolidines / Q000009:adverse effects* / Q000627:therapeutic use; D011960:Receptors, Estrogen / Q000187:drug effects; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use
D004967:Estrogens; D011759:Pyrrolidines; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene